Multiple myeloma

Score 8.1 = 2.3 leading Phase 2+ trials + 1.8 other trial roles + 4 talks + 0 posters. 1 of 3 trials are Phase 2+.

• ASH 2026 267 (oral) · Sonrotoclax in combination with dexamethasone and daratumumab for t(11;14) relapsed/refractory multiple myeloma: Preliminary safety and efficacy results from the phase 1b/2 BGB-11417-105 study
• ASH 2026 421 (oral) · First- and only-in-class CD38xBCMAxCD3 trispecific T-cell engager ISB-2001 (ABBV-2001): Updated Phase 1 (TRIgnite-1) study data demonstrate robust efficacy and tolerability in relapsed/refractory multiple myeloma (RRMM)

• Ph1NCT07221032 · Medical College of Wisconsin · FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
• Ph2NCT07284758 · C4 Therapeutics, Inc. · A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
• Ph1NCT05976555 · Medical College of Wisconsin · Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Score 5.1 = 1.1 leading Phase 2+ trials + 0 other trial roles + 4 talks + 0 posters. 1 of 1 trials are Phase 2+.

• ASH 2026 423 (oral) · ENTRUST-IFM/PETHEMA: Preliminary results of the phase 2 portion of a phase 2/3, multicenter, randomized, open-label study evaluating the efficacy and safety of Etentamig and daratumumab in frail transplant-ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM)
• ASH 2026 424 (oral) · Elranatamab (ELRA) monotherapy versus daratumumab plus pomalidomide and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM): Results from the phase 3 MagnetisMM-5 trial

• Ph2NCT05572229 · University Hospital, Lille · Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma

Score 4.9 = 4.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 3 of 3 trials are Phase 2+.

• Ph1/Ph2NCT06876142 · National Cancer Institute (NCI) · Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
• Ph2NCT06103838 · National Cancer Institute (NCI) · 18F-Fluciclovine PET/CT in Multiple Myeloma
• Ph2NCT04933539 · National Cancer Institute (NCI) · Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

Score 4.2 = 4.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT07284758 · C4 Therapeutics, Inc. · A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
• Ph3NCT06918002 · Intergroupe Francophone du Myelome · Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

Score 3.8 = 3.1 leading Phase 2+ trials + 0.6 other trial roles + 0 talks + 0 posters. 2 of 4 trials are Phase 2+.

• Ph2NCT04876248 · Roswell Park Cancer Institute · Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
• Ph2NCT06627751 · Roswell Park Cancer Institute · Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
• Ph1NCT06622005 · Roswell Park Cancer Institute · SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
• Ph1NCT02334865 · Roswell Park Cancer Institute · SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Score 3.8 = 1.8 leading Phase 2+ trials + 0 other trial roles + 2 talks + 0 posters. 1 of 1 trials are Phase 2+.

• ASH 2026 116 (oral) · BMS-986453, a dual-targeting BCMA×GPRC5D autologous CAR T cell therapy with polyfunctional phenotype: A first-in-human study in patients with relapsed/refractory multiple myeloma

• Ph2NCT06461988 · Stanford University · Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

Score 3.4 = 3 leading Phase 2+ trials + 0.4 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph1NCT06048250 · City of Hope Medical Center · Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
• Ph1/Ph2NCT07463807 · National Cancer Institute (NCI) · Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

Score 3.3 = 3.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 3 of 3 trials are Phase 2+.

• Ph3NCT05243797 · European Myeloma Network B.V. · Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
• Ph2NCT04564703 · Stichting European Myeloma Network · Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
• Ph2NCT07107529 · European Myeloma Network B.V. · Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

Score 3.2 = 3.1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 3 trials are Phase 2+.

• Ph1NCT02886065 · Massachusetts General Hospital · A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM
• Ph2NCT06832865 · Massachusetts General Hospital · ELISA in Relapsed/Refractory MM
• Ph2NCT06138275 · Massachusetts General Hospital · Elranatamab in R/R Multiple Myeloma

Score 3.2 = 3.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT05969860 · Mayo Clinic · At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
• Ph2NCT07285044 · Mayo Clinic · The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Score 3.1 = 2.2 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph1NCT07660939 · Peking University First Hospital · GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
• Ph2/Ph3NCT07319897 · Peking University First Hospital · 68Ga-BCMA PET/CT in Multiple Myeloma

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph3NCT07285239 · PrECOG, LLC. · Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
• Ph3NCT01863550 · ECOG-ACRIN Cancer Research Group · Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07901868 · PETHEMA Foundation · Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07605416 · National Cancer Institute (NCI) · Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07612787 · Centre Hospitalier Universitaire de Saint Etienne · A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07901868 · PETHEMA Foundation · Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2/Ph3NCT07887984 · Alliance for Clinical Trials in Oncology · Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07895017 · University of Virginia · Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT03271632 · Shenzhen Geno-Immune Medical Institute · Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06948084 · National Cancer Institute (NCI) · Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2/Ph3NCT07887984 · Alliance for Clinical Trials in Oncology · Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph3NCT06182774 · Canadian Cancer Trials Group · Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
• Ph2NCT06421675 · Ontario Clinical Oncology Group (OCOG) · Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07601100 · Dana-Farber Cancer Institute · Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07624513 · Dana-Farber Cancer Institute · D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07637578 · SCRI Development Innovations, LLC · A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

Score 2.8 = 2.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07009899 · Medical College of Wisconsin · BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07247097 · Massachusetts General Hospital · ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

Score 2.7 = 2.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07705074 · Martin Huellner · FAPI PET Imaging - An Exploratory Study

Score 2.6 = 2.4 leading Phase 2+ trials + 0.2 other trial roles + 0 talks + 0 posters. 2 of 3 trials are Phase 2+.

• Ph2NCT02538198 · Memorial Sloan Kettering Cancer Center · Lenalidomide Maintenance in Plasma Cell Myeloma
• Ph1NCT05139225 · Memorial Sloan Kettering Cancer Center · A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma
• Ph2NCT07454382 · Memorial Sloan Kettering Cancer Center · A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07649525 · University of Leeds · Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07649525 · University of Leeds · Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07671287 · University of Heidelberg Medical Center · GMMG-HD11/DSMM XXI/64007957MMY3010

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07689058 · Dr. Zaineb Akram · CAR-T in Relapsed/Refractory Multiple Myeloma

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06348147 · UNC Lineberger Comprehensive Cancer Center · Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07689058 · Dr. Zaineb Akram · CAR-T in Relapsed/Refractory Multiple Myeloma

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 3 of 3 trials are Phase 2+.

• Ph3NCT05558319 · PETHEMA Foundation · NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
• Ph2NCT05849610 · PETHEMA Foundation · Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma
• Ph2NCT05527340 · PETHEMA Foundation · Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07053436 · Multiple Myeloma Research Consortium · Horizon Two: HR NDMM (MMRC-100)

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07567014 · NYU Langone Health · Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07638683 · Shanghai Zhongshan Hospital · A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).

Score 2.4 = 2.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 4 of 4 trials are Phase 2+.

• Ph2NCT03315026 · Memorial Sloan Kettering Cancer Center · Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
• Ph2NCT06679829 · Memorial Sloan Kettering Cancer Center · A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
• Ph2NCT03556332 · Memorial Sloan Kettering Cancer Center · A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
• Ph2NCT05393804 · Memorial Sloan Kettering Cancer Center · A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant